Independent safety review approved dose escalation and initiation of next dosing cohortSTAR-LLD generally well tolerated in all subjects dosed to dateOn track to complete dosing of all…
The open-label, randomized, crossover, ascending dose study will assess STAR-LLD safety, tolerability, and pharmacokinetics in healthy subjects On track to complete dosing in May 2022…
PrSandoz® Lenalidomide is approved for the same indications as the reference medicine PrRevlimid®.PrSandoz® Lenalidomide will be distributed through RevAid®, the same program as the…
PrSandoz® Lenalidomide est approuvé pour les mêmes indications que le médicament de référence PrRevlimid®.La distribution de PrSandoz® Lenalidomide se fera par l’intermédiaire du programme…